Abiraterone Acetate in Asymptomatic or Mildly Symptomatic Patients With Metastatic Castration-Resistant Prostate Cancer

Clinical Trial ID NCT00887198

PubWeight™ 71.07‹?›

🔗 Visit the ClinicalTrials.gov page for NCT00887198

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Abiraterone in metastatic prostate cancer without previous chemotherapy. N Engl J Med 2012 15.69
2 Phase II multicenter study of abiraterone acetate plus prednisone therapy in patients with docetaxel-treated castration-resistant prostate cancer. J Clin Oncol 2010 4.64
3 Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol 2015 4.40
4 Updated interim efficacy analysis and long-term safety of abiraterone acetate in metastatic castration-resistant prostate cancer patients without prior chemotherapy (COU-AA-302). Eur Urol 2014 2.46
5 New strategies in metastatic prostate cancer: targeting the androgen receptor signaling pathway. Clin Cancer Res 2011 2.01
6 Novel therapies for metastatic castrate-resistant prostate cancer. J Natl Cancer Inst 2011 1.98
7 Drug resistance in metastatic castration-resistant prostate cancer. Nat Rev Clin Oncol 2010 1.86
8 CYP17 inhibitors for prostate cancer therapy. J Steroid Biochem Mol Biol 2010 1.70
9 Correlation between Prostate-Specific Antigen Kinetics and Overall Survival in Abiraterone Acetate-Treated Castration-Resistant Prostate Cancer Patients. Clin Cancer Res 2015 1.55
10 The changing therapeutic landscape of castration-resistant prostate cancer. Nat Rev Clin Oncol 2011 1.55
11 Abiraterone acetate plus prednisone versus prednisone alone in chemotherapy-naive men with metastatic castration-resistant prostate cancer: patient-reported outcome results of a randomised phase 3 trial. Lancet Oncol 2013 1.51
12 Impact of bone-targeted therapies in chemotherapy-naïve metastatic castration-resistant prostate cancer patients treated with abiraterone acetate: post hoc analysis of study COU-AA-302. Eur Urol 2015 1.42
13 Radiographic progression-free survival as a response biomarker in metastatic castration-resistant prostate cancer: COU-AA-302 results. J Clin Oncol 2015 1.38
14 Androgen action and metabolism in prostate cancer. Mol Cell Endocrinol 2012 1.25
15 Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3. J Clin Oncol 2016 1.21
16 Abiraterone in prostate cancer: a new angle to an old problem. Clin Cancer Res 2012 1.21
17 Androgen receptor antagonists in castration-resistant prostate cancer. Cancer J 2013 1.19
18 Cabazitaxel: a novel second-line treatment for metastatic castration-resistant prostate cancer. Drug Des Devel Ther 2011 1.14
19 Novel targeted therapeutics for metastatic castration-resistant prostate cancer. Cancer Lett 2009 1.04
20 Emerging novel therapies in the treatment of castrate-resistant prostate cancer. Can Urol Assoc J 2011 1.04
21 Update on options for treatment of metastatic castration-resistant prostate cancer. Onco Targets Ther 2010 1.00
22 The changing landscape in the treatment of metastatic castration-resistant prostate cancer. Ther Adv Med Oncol 2013 0.97
23 Critical appraisal of cabazitaxel in the management of advanced prostate cancer. Clin Interv Aging 2010 0.96
24 Androgen deprivation therapy as adjuvant/neoadjuvant to radiotherapy for high-risk localised and locally advanced prostate cancer: recent developments. Br J Cancer 2011 0.94
25 Prostate cancer in 2011: redefining the therapeutic landscape for CRPC. Nat Rev Urol 2012 0.91
26 Novel therapeutic strategies for metastatic prostate cancer in the post-docetaxel setting. Oncologist 2011 0.90
27 Targeting the androgen receptor in the management of castration-resistant prostate cancer: rationale, progress, and future directions. Curr Oncol 2012 0.89
28 Prostate cancer in 2011: Hitting old targets better and identifying new targets. Nat Rev Clin Oncol 2012 0.88
29 Improvements in Radiographic Progression-Free Survival Stratified by ERG Gene Status in Metastatic Castration-Resistant Prostate Cancer Patients Treated with Abiraterone Acetate. Clin Cancer Res 2015 0.88
30 Current paradigms and evolving concepts in metastatic castration-resistant prostate cancer. Asian J Androl 2011 0.87
31 Emerging molecularly targeted therapies in castration refractory prostate cancer. Prostate Cancer 2013 0.83
32 Phase III data for abiraterone in an evolving landscape for castration-resistant prostate cancer. Maturitas 2010 0.82
33 Emerging targeted therapies for castration-resistant prostate cancer. Front Endocrinol (Lausanne) 2012 0.81
34 Sipuleucel-T: harbinger of a new age of therapeutics for prostate cancer. Expert Rev Vaccines 2011 0.80
35 Does Gleason score at initial diagnosis predict efficacy of abiraterone acetate therapy in patients with metastatic castration-resistant prostate cancer? An analysis of abiraterone acetate phase III trials. Ann Oncol 2015 0.80
36 New insights into the androgen-targeted therapies and epigenetic therapies in prostate cancer. Prostate Cancer 2011 0.79
37 Response to subsequent docetaxel in a patient cohort with metastatic castration-resistant prostate cancer after abiraterone acetate treatment. Clin Genitourin Cancer 2014 0.79
38 Research in castration-resistant prostate cancer: what does the future hold? Curr Oncol 2010 0.79
39 Medical strategies for treatment of castration resistant prostate cancer (CRPC) docetaxel resistant. Cancer Biol Ther 2012 0.79
40 A changing landscape in castration-resistant prostate cancer treatment. Front Endocrinol (Lausanne) 2012 0.78
41 Sipuleucel-T for therapy of asymptomatic or minimally symptomatic, castrate-refractory prostate cancer: an update and perspective among other treatments. Onco Targets Ther 2011 0.78
42 Current and emerging treatment options for castration-resistant prostate cancer: a focus on immunotherapy. J Clin Immunol 2011 0.78
43 Efficacy and Safety of Abiraterone Acetate in Elderly (75 Years or Older) Chemotherapy Naïve Patients with Metastatic Castration Resistant Prostate Cancer. J Urol 2015 0.78
44 Novel Androgen Deprivation Therapy (ADT) in the Treatment of Advanced Prostate Cancer. Drug Discov Today Ther Strateg 2010 0.76
45 Abiraterone acetate, an inhibitor of adrenal androgen synthesis in "hormone refractory prostate cancer". Indian J Med Paediatr Oncol 2011 0.75
46 Abiraterone acetate. Drugs R D 2010 0.75
47 Management of metastatic castration-resistant prostate cancer. Eur Urol Rev 2011 0.75
48 The European medicines agency review of abiraterone for the treatment of metastatic castration-resistant prostate cancer in adult men after docetaxel chemotherapy and in chemotherapy-naive disease: summary of the scientific assessment of the committee for medicinal products for human use. Oncologist 2013 0.75
Next 100